CANCER:

Glioma

News alerts, weekly reports and conference planners

Related cancers:

‹

CNS Tumor (502)

Brain Cancer (495)

Neuroblastoma (43)

Pituitary Gland Carcinoma (10)

Pituitary Gland Carcinoma (10)

Meningioma (7)

›

MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	temozolomide Sensitive: A2 - Guideline Transl Oncol - 1 week (New D) temozolomide Sensitive : A2 Transl Oncol - 1wk	temozolomide Sensitive: A2 - Guideline Transl Oncol - 1 week temozolomide Sensitive : A2 Transl Oncol - 1 week - (New D)
BRAF V600	Glioma	BRAF V600	Glioma	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) FORE-8394 Sensitive : C3 ESMO 2022 - 3wk	FORE-8394 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks FORE-8394 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
IDH wild-type	Glioblastoma	IDH wild-type	Glioblastoma	bevacizumab + retifanlimab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab + retifanlimab Sensitive : C3 ESMO 2022 - 3wk	bevacizumab + retifanlimab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab + retifanlimab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
No biomarker	Glioblastoma	No biomarker	Glioblastoma	Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval Byvasda (bevacizumab biosimilar) Sensitive : A1	Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval Byvasda (bevacizumab biosimilar) Sensitive : A1
No biomarker	Astrocytoma	No biomarker	Astrocytoma	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Astrocytoma	No biomarker	Astrocytoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Ependymoma	No biomarker	Ependymoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Anaplastic Astrocytoma	No biomarker	Anaplastic Astrocytoma	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Glioma	No biomarker	Glioma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1	temozolomide Sensitive: A1 - Approval temozolomide Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1	carmustine Sensitive: A1 - Approval carmustine Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval Krabeva (bevacizumab biosimilar) Sensitive : A1
No biomarker	Glioma	No biomarker	Glioma	teserpaturev Sensitive: A1 - Approval teserpaturev Sensitive : A1	teserpaturev Sensitive: A1 - Approval teserpaturev Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1
IDH1 mutation	Astrocytoma	IDH1 mutation	Astrocytoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
BRAF V600E	Glioblastoma	BRAF V600E	Glioblastoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	PCV Sensitive: A2 - Guideline PCV Sensitive : A2	PCV Sensitive: A2 - Guideline PCV Sensitive : A2
No biomarker	Anaplastic Astrocytoma	No biomarker	Anaplastic Astrocytoma	PCV Sensitive: A2 - Guideline PCV Sensitive : A2	PCV Sensitive: A2 - Guideline PCV Sensitive : A2
No biomarker	Glioma	No biomarker	Glioma	PCV Sensitive: A2 - Guideline PCV Sensitive : A2	PCV Sensitive: A2 - Guideline PCV Sensitive : A2
IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	IDH2 mutation + Chr del(1p) + Chr del(19q)	Oligodendroglioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker	Glioma	No biomarker	Glioma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1
No biomarker	Glioma	No biomarker	Glioma	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2	bevacizumab Sensitive: A2 - Guideline bevacizumab Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
BRAF V600E	Ganglioglioma	BRAF V600E	Ganglioglioma	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : C1	vemurafenib Sensitive: A2 - Guideline vemurafenib Sensitive : C1
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : C1
No biomarker	Astrocytoma	No biomarker	Astrocytoma	lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive : A2	lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive : A2
No biomarker	Glioblastoma	No biomarker	Glioblastoma	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2	lomustine Sensitive: A2 - Guideline lomustine Sensitive : A2
No biomarker	Glioblastoma	No biomarker	Glioblastoma	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
BRAF V600E	Astrocytoma	BRAF V600E	Astrocytoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2	vemurafenib + cobimetinib Sensitive: A2 - Guideline vemurafenib + cobimetinib Sensitive : A2
No biomarker	Astrocytoma	No biomarker	Astrocytoma	temozolomide gel Sensitive: A2 - Guideline temozolomide gel Sensitive : A2	temozolomide gel Sensitive: A2 - Guideline temozolomide gel Sensitive : A2
BRAF V600E	Glioma	BRAF V600E	Glioma	selumetinib Sensitive: A2 - Guideline selumetinib Sensitive : A2	selumetinib Sensitive: A2 - Guideline selumetinib Sensitive : A2

Glioma

Associations(455)

Associations
(455)